Arena Pharmaceuticals, Inc. (ARNA)
(Delayed Data from NSDQ)
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene
by Zacks Equity Research
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Company News For Mar 21, 2018
by Zacks Equity Research
Companies in the news are: ARNA,MULE,CRM,PLCE,HQY
Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
by Zacks Equity Research
Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.
Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y
by Zacks Equity Research
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Options Traders Expect Huge Moves in Arena Pharmaceuticals (ARNA) Stock
by Zacks Equity Research
Surging implied volatility makes Arena Pharmaceuticals (ARNA) stock lucrative to the option traders.
Arena (ARNA) Posts Narrower-Than-Expected Q4 Loss, Shares Up
by Zacks Equity Research
Arena (ARNA) posted narrower-than-expected loss in the fourth quarter of 2017. However, revenues decreased significantly year over year.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
by Zacks Equity Research
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.
Orexigen Struggles as Contrave Commercialization Costs Rise
by Zacks Equity Research
Orexigen (OREX) hurt by higher commercialization costs related to Contrave.
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
by Zacks Equity Research
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.
Orexigen's (OREX) Contrave Sales Improving on Promotions
by Zacks Equity Research
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.
Arena Pharmaceuticals (ARNA) Down 1.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) second-quarter earnings may suffer from high operating cost and low revenues from the ambulatory service unit.
What's in the Cards for Kite Pharma (KITE) in Q2 Earnings
by Zacks Equity Research
With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.
Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in Japan, which drove the company's top line. The company is also working on expanding its pipeline and Amitizia's label.
BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.
Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.